IC
DCPH

Ikarian Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Ikarian Capital’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-800
Closed -$8K – 215
2021
Q4 		$8K Buy
+800
New +$15K ﹤0.01% 183
2020
Q4 		– Sell
-100,000
Closed -$5.13M – 255
2020
Q3 		$5.13M Hold
100,000
– – 0.37% 68
2020
Q2 		$5.97M Buy
+100,000
New +$5.35M 0.48% 61

Other funds holding DCPH

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's DCPH Position: Q3 2023 in Review

Ikarian Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q3 2023, closing a stake of 174,510 shares — an estimated $2.46M sold.

Ikarian Capital first reported a position in DCPH in Q3 2022 and held it in 4 quarters. The position peaked at $9.11M in Q3 2022. 157 funds tracked by Wall St. Rank hold DCPH as of Q3 2023.

  • Ikarian Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 174,510 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $2.46M.
  • Ikarian Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Ikarian Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $9.11M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.